Human papillomavirus testing as an optional screening tool in low-resource sett...

• Autor(es): Longatto Filho, Adhemar ; Eržen, M. ; Branca, M. ; Roteli-Martins, C. ; Naud, P. ; Derchain, S. F. ; Hammes, L. ; Sarian, L. O. ; Bragança, J. F. ; Matos, J. C. ; Gontijo, R. ; Lima, T. P. ; Maeda, Marina Yoshiê Sakamoto ; Tatti, S. ; Syrjänen, K. ; Dôres, Gerson B. das ; Lörincz, A. ; Syrjänen, K.
• Data: 2006
• Identificador Persistente: http://hdl.handle.net/1822/5786
• Origem: RepositóriUM - Universidade do Minho
• Assunto(s): Cervical cancer; HPV testing; Low-resource setting; Screening
• Tipo de Documento: Artigo
• Idioma: Inglês

Descrição

Hybrid capture II (HC II) test for oncogenic human papillomaviruses (HPV) was carried out in a cohort of 4284 women at their first clinical visit. Overall prevalence of HPV was 17.1%, decreasing with age from 33.9% among women below 20 years to only 11.0% among those older than 41 years. HPV prevalence was significantly higher among current smokers (odds ratio [OR] ¼ 1.31; 95% CI 1.1–1.6), in women with two or more lifetime sexual partners (OR ¼ 1.9; 95% CI 1.6–2.4), and those women with two or more sexual partners during the past 12 months prior to examination (OR ¼ 1.6; 95% CI 1.2–2.2). HPV detection increased in parallel with increasing cytologic abnormality, being highest in women with high-grade squamous intraepithelial lesion (P ¼ 0.001). Specificity of the HPV test in detecting histologically confirmed cervical disease was 85% (95% CI 83.9–86.1). Sensitivity of the HPV test in detecting histologic abnormalities increased in parallel with disease severity, ranging from 51.5% for cervical intraepithelial neoplasia (CIN) 1 to 96.5% for CIN 3 and 100.0% for cancer, with respective decline of positive predictive value. These data suggest that HPV testing with HC II assay might be a viable screening tool among this population with relatively high prevalence of cervical disease.